Department of Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
BMC Cancer. 2021 Dec 20;21(1):1352. doi: 10.1186/s12885-021-09098-4.
It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining for CD30. Therefore, we devised a notation that we termed proportion of immunoreactivity/expression for FCM (PRIME-F notation), based on the cellular proportion showing different antigen-antibody reactivity.
We retrospectively compiled 211 cases of T-cell lymphoma, assessed via FCM, from major hospitals in Miyagi Prefecture from January 2012 to January 2019, and compared 52 of these cases with the immunohistochemical immunoreactive (IR) pattern of CD30 (PRIME-I notation). The PRIME-F notation was divided into five levels: notations starting with "-" followed by 3, 2, and 1 ">" correspond to level-I, level-II, or level-III; notations starting with "(dim)+" correspond to level-IV; and those starting with "+" or "(bright)+" correspond to level-V.
The 52 cases of PRIME-F notation with "+" included 16 cases of peripheral T-cell lymphoma (PTCL/NOS), 3 of follicular T-cell lymphoma (FTL), 3 of angioimmunoblastic T-cell lymphoma (AITL), 6 of extranodal NK/T-cell lymphoma/nasal type (ENKL), 18 of adult T-cell lymphoma (ATL), and 6 cases of anaplastic large cell lymphoma (ALCL). Eight of the 52 cases were immunohistochemically CD30-negative. In the PRIME-F level-I to III group (excluding false-positive cases), 21.7% (5 out of 23 cases) were < 10% positive for CD30 upon immunohistochemistry (IHC). Contrarily, in the level-IV & -V group, no CD30 positivity rate of < 10% upon IHC was found (0%) (p = 0.0497). In level-IV, 42.9% of cases presented a CD30 negative rate > 1/3 upon IHC, while in level-V, only 7.1% (one out of 14 cases) did. The CD30 negative rate tended to be low (p = 0.0877) in level-V.
To our knowledge, this is the first report describing the correspondence between FCM and immunohistochemistry findings for CD30 through newly proposed notations. The PRIME-F and PRIME-I notations for CD30 showed a minor positive correlation. The PRIME notation is considered universally applicable to antibodies, and notations of both FCM and IHC show great potential for big data.
在 T 细胞淋巴瘤病例中，确认 CD30 表达很重要，但免疫组织化学染色检测 CD30 并不常见，并且尚未对流式细胞术（FCM）和 CD30 免疫组织化学染色的结果进行比较。因此，我们设计了一种基于细胞显示不同抗原-抗体反应性的比例的符号，我们称之为 FCM 的免疫反应性/表达比例（PRIME-F 符号）。
我们回顾性地从 2012 年 1 月至 2019 年 1 月在宫城县的主要医院收集了 211 例 T 细胞淋巴瘤病例，通过 FCM 进行评估，并将其中的 52 例与 CD30 的免疫反应性（IR）模式（PRIME-I 符号）进行了比较。PRIME-F 符号分为五个级别：以“-”开头，后跟 3、2 和 1“>”的符号对应于级别-I、级别-II 或级别-III；以“（dim）+”开头的符号对应于级别-IV；以“+”或“（bright）+”开头的符号对应于级别-V。
52 例 PRIME-F 符号为“+”的病例包括 16 例外周 T 细胞淋巴瘤（PTCL/NOS）、3 例滤泡性 T 细胞淋巴瘤（FTL）、3 例血管免疫母细胞性 T 细胞淋巴瘤（AITL）、6 例结外 NK/T 细胞淋巴瘤/鼻型（ENKL）、18 例成人 T 细胞淋巴瘤（ATL）和 6 例间变性大细胞淋巴瘤（ALCL）。52 例中有 8 例免疫组织化学检查 CD30 阴性。在 PRIME-F 级别-I 到 III 组（不包括假阳性病例）中，21.7%（23 例中有 5 例）的 CD30 免疫组织化学阳性率<10%。相反，在级别-IV 和-V 组中，未发现 CD30 免疫组织化学阳性率<10%（0%）（p=0.0497）。在级别-IV 中，42.9%的病例 CD30 免疫组织化学阴性率>1/3，而在级别-V 中，只有 7.1%（14 例中有 1 例）。在级别-V 中，CD30 阴性率似乎较低（p=0.0877）。
据我们所知，这是首次通过新提出的符号描述 FCM 与 CD30 免疫组织化学结果之间的对应关系。CD30 的 PRIME-F 和 PRIME-I 符号显示出轻微的正相关。PRIME 符号被认为普遍适用于抗体，并且 FCM 和 IHC 的符号都具有大数据的巨大潜力。
